BR112012006149A2 - composição farmacêutica. - Google Patents
composição farmacêutica.Info
- Publication number
- BR112012006149A2 BR112012006149A2 BR112012006149A BR112012006149A BR112012006149A2 BR 112012006149 A2 BR112012006149 A2 BR 112012006149A2 BR 112012006149 A BR112012006149 A BR 112012006149A BR 112012006149 A BR112012006149 A BR 112012006149A BR 112012006149 A2 BR112012006149 A2 BR 112012006149A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- reducing
- combination
- agent
- ccbs
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- AKQDXNFPEFHRLS-UHFFFAOYSA-N (1-benzylindazol-3-yl)methanol Chemical class C12=CC=CC=C2C(CO)=NN1CC1=CC=CC=C1 AKQDXNFPEFHRLS-UHFFFAOYSA-N 0.000 abstract 1
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
a presente invenção refere-se a uma composição farmacêutica compreendendo uma combinação de derivado de 1-benzil-3-hidroximetilindazol, um agente redutor de pressão selecionado dentre os inibidores de ace, os inibidores de renina, arbs e ccbs, e/ou um agente redutor de colesterol selecionado dentro os derivados da estatina. a combinação mostou uma atividade aditiva e sinergística em reduzir os níveis de mcp-1, assim significativamente melhorando a inibição da resposta inflamatória e consequentemente reduzingo as complicações que ocorrem nos pacientes sofrendo das doenças inflamatórias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09425368 | 2009-09-23 | ||
| PCT/EP2010/062979 WO2011036047A1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012006149A2 true BR112012006149A2 (pt) | 2016-06-28 |
Family
ID=41722750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012006149A BR112012006149A2 (pt) | 2009-09-23 | 2010-09-03 | composição farmacêutica. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9492542B2 (pt) |
| EP (1) | EP2480224B1 (pt) |
| JP (2) | JP2013505278A (pt) |
| KR (1) | KR101774402B1 (pt) |
| CN (1) | CN102573827B (pt) |
| AR (1) | AR078307A1 (pt) |
| AU (1) | AU2010297405B2 (pt) |
| BR (1) | BR112012006149A2 (pt) |
| CA (1) | CA2760180C (pt) |
| CY (1) | CY1119125T1 (pt) |
| DK (1) | DK2480224T3 (pt) |
| EA (1) | EA021485B1 (pt) |
| ES (1) | ES2637024T3 (pt) |
| GE (1) | GEP20146067B (pt) |
| HR (1) | HRP20171209T1 (pt) |
| HU (1) | HUE033102T2 (pt) |
| IL (1) | IL218001A (pt) |
| LT (1) | LT2480224T (pt) |
| MX (1) | MX347957B (pt) |
| PL (1) | PL2480224T3 (pt) |
| PT (1) | PT2480224T (pt) |
| SG (2) | SG10201405408YA (pt) |
| SI (1) | SI2480224T1 (pt) |
| SM (1) | SMT201700330T1 (pt) |
| UA (1) | UA108742C2 (pt) |
| WO (1) | WO2011036047A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US11221321B2 (en) * | 2019-05-29 | 2022-01-11 | Imam Abdulrahman Bin Faisal University | Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof |
| EP3990433B1 (en) | 2019-06-25 | 2026-05-20 | Translatum Medicus Inc | PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| JP2023082437A (ja) * | 2021-12-02 | 2023-06-14 | 学校法人東京薬科大学 | Ｃｃｌ８による免疫細胞の動員が関与する炎症を抑制するための組成物 |
| CN116688135B (zh) * | 2023-07-28 | 2024-10-29 | 四川大学华西医院 | 一种骨关节炎药物治疗组合物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI88400C (fi) | 1984-08-06 | 1993-05-10 | Upjohn Co | Foerfarande foer framstaellning av renin inhiberande peptider |
| MY103189A (en) | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| CA2023099A1 (en) | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
| US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| TW198712B (pt) | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| IT1253703B (it) | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| IT1276031B1 (it) | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| SE9600120D0 (sv) | 1996-01-15 | 1996-01-15 | Astra Ab | Novel medical use |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| US6268377B1 (en) | 1998-09-28 | 2001-07-31 | Merck & Co., Inc. | Method for treating androgen-related conditions |
| GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| JP2005501815A (ja) | 2001-05-14 | 2005-01-20 | メルク エンド カムパニー インコーポレーテッド | 治療方法 |
| US20030060502A1 (en) | 2001-09-19 | 2003-03-27 | Francois Mach | Treatment of diabetes with statins (HMG-COa reductase inhibitors) |
| US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20070060549A1 (en) | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| EP1806137A4 (en) | 2004-10-29 | 2011-03-30 | Kowa Co | THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE |
| EP2526937A1 (en) | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
| WO2008084504A2 (en) | 2007-01-12 | 2008-07-17 | Rubicon Research Private Limited | Pharmaceutical compositions of angiotensin ii receptor blockers |
| EP2481408A3 (en) * | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| KR101581828B1 (ko) * | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
-
2010
- 2010-03-09 UA UAA201203482A patent/UA108742C2/uk unknown
- 2010-09-03 CN CN201080042390.9A patent/CN102573827B/zh not_active Expired - Fee Related
- 2010-09-03 EP EP10747897.6A patent/EP2480224B1/en active Active
- 2010-09-03 BR BR112012006149A patent/BR112012006149A2/pt not_active Application Discontinuation
- 2010-09-03 HU HUE10747897A patent/HUE033102T2/en unknown
- 2010-09-03 EA EA201270449A patent/EA021485B1/ru not_active IP Right Cessation
- 2010-09-03 JP JP2012530204A patent/JP2013505278A/ja active Pending
- 2010-09-03 SG SG10201405408YA patent/SG10201405408YA/en unknown
- 2010-09-03 CA CA2760180A patent/CA2760180C/en not_active Expired - Fee Related
- 2010-09-03 US US13/497,175 patent/US9492542B2/en not_active Expired - Fee Related
- 2010-09-03 SG SG2012010302A patent/SG178414A1/en unknown
- 2010-09-03 PL PL10747897T patent/PL2480224T3/pl unknown
- 2010-09-03 AU AU2010297405A patent/AU2010297405B2/en not_active Ceased
- 2010-09-03 KR KR1020127007411A patent/KR101774402B1/ko not_active Expired - Fee Related
- 2010-09-03 ES ES10747897.6T patent/ES2637024T3/es active Active
- 2010-09-03 SM SM20170330T patent/SMT201700330T1/it unknown
- 2010-09-03 WO PCT/EP2010/062979 patent/WO2011036047A1/en not_active Ceased
- 2010-09-03 MX MX2012003485A patent/MX347957B/es active IP Right Grant
- 2010-09-03 GE GEAP201012675A patent/GEP20146067B/en unknown
- 2010-09-03 HR HRP20171209TT patent/HRP20171209T1/hr unknown
- 2010-09-03 PT PT107478976T patent/PT2480224T/pt unknown
- 2010-09-03 SI SI201031512T patent/SI2480224T1/sl unknown
- 2010-09-03 DK DK10747897.6T patent/DK2480224T3/en active
- 2010-09-03 LT LTEP10747897.6T patent/LT2480224T/lt unknown
- 2010-09-22 AR ARP100103447A patent/AR078307A1/es unknown
-
2012
- 2012-02-09 IL IL218001A patent/IL218001A/en not_active IP Right Cessation
-
2015
- 2015-07-31 JP JP2015152596A patent/JP6122470B2/ja active Active
-
2017
- 2017-07-28 CY CY20171100808T patent/CY1119125T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501319A1 (en) | Fatty acid acetylated salicylates and their uses | |
| BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
| BRPI1015539A2 (pt) | composições e métodos para tratamento de queimaduras | |
| MX394763B (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina | |
| WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
| PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| IN2012DN02661A (pt) | ||
| TN2012000458A1 (en) | Uses of dgat1 inhibitors | |
| PH12013500892B1 (en) | Composition for use in the prevention and\or treatment of skin conditions and skin diseases | |
| BR112012018022A2 (pt) | inibição de sinalização axl em terapia antimetastática. | |
| WO2012156531A9 (en) | Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions | |
| BR112013006673A2 (pt) | produtos terapêuticos para câncer de mama | |
| WO2011051966A3 (en) | Pharmaceutical compositions for treatment/prophylaxis of non-alcoholic fatty liver disease | |
| CY1119125T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια προκαλουμενων απο mcp-1 φλεγμονωδων νοσων | |
| WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
| MY168759A (en) | Pharmaceutical compositions comprising modified fucans and methods relating thereto | |
| BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
| MX2015016494A (es) | Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa. | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| BR112014009365A2 (pt) | método para inibição da atividade de deubiquitinação | |
| WO2010030976A3 (en) | Methods and compositions for inhibiting atherosclerosis and vascular inflammation | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| BR112014030288A2 (pt) | composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |